 |
014 Vaccine Trial |
       |
Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.
Source: J Infect Dis 2001 May 1;183(9):1343-52
Authors: Belshe RB, Stevens C, Gorse GJ, Buchbinder S, Weinhold
K,
Sheppard H,
Stablein D, Self
S, McNamara J, Frey S, Flores J, Excler JL, Klein M, Habib RE, Duliege AM, Harro C,
Corey L, Keefer M, Mulligan M, Wright P, Celum C, Judson F, Mayer K, McKirnan D, Marmor
M, Woody G; National Institute of Allergy and Infectious Diseases AIDS Vaccine
Evaluation Group and HIV Network for Prevention Trials (HIVNET).
Publication Info: Department of Internal Medicine, Saint Louis University
School
of Medicine and St. Louis
Veterans Affairs Medical Center, 3635 Vista Ave. (FDT-8N) St. Louis, MO 63110, USA.
Belsherb@slu.edu [Confidentiality cannot be guaranteed for information provided
via e-mail. People visiting websites from public or work machines may be leaving
traces of their visits on those machines.]
Abstract: Live attenuated viral vectors that express human
immunodeficiency virus
(HIV) antigens
are being developed as potential vaccines to prevent HIV infection. The first phase 2
trial with a canarypox vector (vCP205, which expresses gp120, p55, and protease) was
conducted in 435 volunteers with and without gp120 boosting, to expand the safety
database and to compare the immunogenicity of the vector in volunteers who were at
higher risk with that in volunteers at lower risk for HIV infection. Neutralizing
antibodies to the MN strain were stimulated in 94% of volunteers given vCP205 plus gp120
and in 56% of volunteers given vCP205 alone. CD8(+) cytotoxic T lymphocyte cells
developed at some time point in 33% of volunteers given vCP205, with or without gp120.
Phase 3 field trials with these or similar vaccines are needed, to determine whether
efficacy in preventing HIV infection or in slowing disease progression among vaccinees
who become infected is associated with the level and types of immune responses that were
induced by the vaccines in this study.
|
| | |